Fulgent Genetics
Fulgent Genetics' Q2 Revenues Rise 5 Percent
The firm reiterated its full-year 2024 guidance and also increased its EPS guide.
Fulgent Genetics Q4 Core Revenues Rise 21 Percent
Including COVID-related sales, full revenues for the quarter increased approximately 4 percent compared to Q4 2022.
CooperSurgical, Fulgent Genetics to Offer Newborn Genetic Screening Panels
Families within CooperSurgical's Cord Blood Registry will have exclusive access to three screening tests from Fulgent Genetics.
UBS Initiates Coverage of Bio-Rad Laboratories, Fulgent Genetics, Bio-Techne
The global financial services firm gave ratings of Buy, Neutral, and Buy to Bio-Rad, Fulgent, and Bio-Techne, respectively.
Fulgent Genetics Core Revenues Rise 17 Percent
Total revenues were down approximately 20 percent, which the El Monte, California-based molecular diagnostics firm attributed to a year-over-year decline in COVID-19 testing.
Aug 4, 2023
Fulgent Genetics Core Revenues Jump 48 Percent
May 11, 2022
Apr 21, 2022
Feb 23, 2022